… This report represents the first analysis of OS benefit with the combination of erlotinib
plus bevacizumab vs erlotinib monotherapy in EGFR+ NSCLC. The significant PFS benefit …

… erlotinib and bevacizumab with erlotinib alone in the treatment of patients with advanced
non-small cell lung cancer (… ) comparing erlotinib plus bevacizumab with erlotinib in NSCLC …

… the combination of bevacizumab and erlotinib was compared with erlotinib monotherapy to
evaluate activity in patients with non-small-cell lung cancer (NSCLC) who were not stratified …

… The most frequent G3-5 toxicities were rash and diarrhea in studies using both erlotinib
monotherapy and combination therapy. Furthermore, the results showed that, when using …

… EGFR TKIs including erlotinib and … monotherapy or in combination with erlotinib with no
dose-limiting toxicities observed. Of the 14 patients who received emibetuzumab plus erlotinib, 2 …

… Our meta-analysis indicates that compared with monotherapy, erlotinib+bevacizumab
combination therapy prolongs PFS of patients with NSCLC, but cannot extend OS or elevate ORR. …

… cell lung carcinoma is a challenging disease worldwide. This study aims to determine whether
combining erlotinib, … concentration (IC 50 ) of erlotinib monotherapy was 5.3 μM at 24hrs, …

… Herein we describe our experience with erlotinib monotherapy … of NSCLC who underwent
erlotinib monotherapy from 2005-… all patients who received erlotinib monotherapy (n = 187), …

… Conversely, the final results of the NEJ026 study comparing the association of erlotinib-bevacizumab
to erlotinib monotherapy failed to improve OS, might be related to the long post …

… The JAK1/2 and TBK1 inhibitor momelotinib in combination with erlotinib did not appear
to enhance benefit over the historical data of erlotinib monotherapy in patients with EGFR-…